CTRI/2021/04/032522已完成3 期
A Phase III, double-blind, randomized, multicenter prospective study to evaluate the efficacy and safety of fixed dose combination of Metformin HCl and Myo-inositol as compared to Metformin in subjects with polycystic ovary syndrome (PCOS).
Eris Lifesciences Ltd0 个研究点目标入组 173 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 173
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Adult female subjects 18 to40 (both inclusive) years of age.
- •2.Subject diagnosed of polycystic ovary syndrome (PCOS), according to Rotterdam Criteria, if she has 2 of the following 3 manifestations:
- •Hyperandrogenism (defined by elevated free testosterone concentration; or Ferriman-Gallwey Score of greater than or equal to 8).
- •Disturbed ovulatory function with chronic oligomenorrhea (cycles of > 35 days less than nine cycles per year), or amenorrhea (cycle length > 12 weeks) after negative screening pregnancy test.
- •Polycystic ovary as shown by transvaginal ultrasonography (TVUS).
- •NOTE: As per FIGO recommendation to characterize menstrual irregularities and accordingly, those subjects who are having menstrual cycle of more than 38 days will be included in the study.
- •3.Subjects with established insulin resistance (by using HOMA IR model, which can be supported by clinical evidences of BMI more than 23 or impaired GTT or cutaneous manifestations like acanthosisnigricans etc.)
- •4.Subject is willing and able to take oral medications.
- •5.Subject is willing to continue with regular follow-up as required for the study.
- •6.Subject willing to observe barrier contraception (oral contraceptives or any other hormonal medications not to be consumed) during the study period.
排除标准
- •1.Pregnant or lactating women (urinary pregnancy test will be applied at screening).
- •2.Subject with previous medical history (either laboratory or clinical) or currently having any of the following conditions: Cushings syndrome, late onset of congenital adrenal hyperplasia, androgen-secreting tumours, uncontrolled thyroid disease, hyperprolactinemia or any other hormonal dysfunction.
- •3.Subject with history or current status of diabetes mellitus, uncontrolled hypertension, symptomatic cardiovascular diseases.
- •4.Subject with any acute or chronic infections at the time of screening.
- •5.Subject with history of malignancies.
- •6.Subject with known history of gynaecological surgery.
- •7.Subject having impaired renal or liver function at the time of screening.
- •8.Subject who is currently on a medically-assisted weight loss program with medication or surgical procedures.
- •9.Subject currently having laparoscopic ovarian diathermy (LOD).
- •10.Subject who is willing to or currently undergoing in vitro fertilization (IVF), or considering participation in any artificial reproduction techniques (ART) program.
- •11.Subject who has received or is currently receiving following medication within past 3months of screening: clomiphene citrate; insulin sensitizers like Metformin and thiazolidinediones; aromatase inhibitors like anastrozole, letrozole; glucocorticoids; gonadotropins; gonadotropin-releasing hormone agonists (GnRHa); hormonal contraceptives; antiandrogens like spironolactone, cyproterone acetate (CPA), and flutamide; anti-obesity drugs; or any traditional or herbal medicines.
- •12.Known history or current use of alcohol, smoker or tobacco user, or Subject with unstable mental illness.
- •13.Subject is participating or has participated in any other clinical trial within last 30 days prior to screening.
- •14.In the opinion of the investigator, the Subject is not eligible to participate or may not complythe study procedures.
- •15.Subject having contraindication or known allergy to any of the study treatment.
研究者
相似试验
进行中（未招募）
不适用
Safety and immunogenicity study of GSK Biologicals’ Quadrivalent Influenza Vaccine (GSK2321138A) manufactured with a new process in adults and children.EUCTR2014-000955-10-CZGlaxoSmithKline Biologicals1,860
进行中（未招募）
不适用
Safety and immunogenicity study of GSK Biologicals’ Quadrivalent Influenza Vaccine (GSK2321138A) manufactured with a new process in adults and children.EUCTR2014-000955-10-DEGlaxoSmithKline Biologicals1,860
进行中（未招募）
不适用
Safety and immunogenicity study of GSK Biologicals? Quadrivalent Influenza Vaccine (GSK2321138A) manufactured with a new process in adults and children.Healthy volunteers (Active immunization of adults and children against influenza)MedDRA version: 17.0Level: LLTClassification code 10059430Term: Influenza immunizationSystem Organ Class: 100000004865MedDRA version: 17.0Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 100000004862MedDRA version: 17.0Level: LLTClassification code 10022003Term: Influenza B virus infectionSystem Organ Class: 100000004862EUCTR2014-000955-10-ESGlaxoSmithKline1,860
进行中（未招募）
1 期
A Phase III, randomized, double-blind, multicenter study to assess the efficacy and safety of OCTAPLEX, a four-factor prothrombin complex concentrate (4F-PCC), compared to the 4F-PCC Beriplex® P/N (Kcentra), for the reversal of vitamin K antagonist induced anticoagulation in patients needing urgent surgery with significant bleeding risk.EUCTR2016-002649-41-BGOctapharma Pharmazeutika Produktionsges.m.b.H370
进行中（未招募）
1 期
A Phase III, randomized, double-blind, multicenter study to assess the efficacy and safety of OCTAPLEX, a four-factor prothrombin complex concentrate (4F-PCC), compared to the 4F-PCC Beriplex® P/N (Kcentra), for the reversal of vitamin K antagonist induced anticoagulation in patients needing urgent surgery with significant bleeding risk.EUCTR2016-002649-41-ROOctapharma Pharmazeutika Produktionsges.m.b.H370